Rhythm Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
15analysts covering
FY Revenue (est.)
$313.6Mnext fiscal year
FY EPS (est.)
-$3.07next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Global Net Product Sales of IMCIVREE Quarterly60.1MTarget: Continued sequential growth driven by BBS and acquired HO
U.S. Patient Start Forms for Acquired Hypothalamic Obesity (HO) Quarterly150.0Target: Rapid expansion following March 2026 FDA approval
Non-GAAP Operating Expenses Annually105.3MTarget: 385000000 to 415000000
Watch Items
- Regulatory approval and commercial launch of IMCIVREE in JapanTrigger: PMDA decision expected by year-end 2026Action: Monitor PMDA regulatory updates and launch preparation milestones
- Phase 3 clinical trial initiation for setmelanotide in Prader-Willi Syndrome (PWS)Trigger: Following positive Phase 2 interim six-month data in June 2026Action: Track trial design finalization, FDA alignment, and first patient dosed
- Cash runway and burn rate managementTrigger: Cash balance of $340.6 million as of March 31, 2026Action: Evaluate quarterly cash consumption against the projected runway into late 2027
Research as of 19 Jun 2026